Real-World Patient Perceptions of GLP-1 RAs and SGLT-2is with Cardiorenal Benefits

被引：0
|
作者：
Lambert, Natalie
Clark, Callahan
McCoy, Rozalina G.
Wong, Alyssa
Cook, David J.
机构：
来源：
DIABETES | 2022年 / 71卷
关键词：
D O I：
10.2337/db22-618-P
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
618-P
引用
收藏
页数：2
相关论文
共 50 条
  • [21] GLP-1 receptor agonists and the risk of atrial fibrillation: a real-world evidence
    Shin, J. I.
    Xu, Y.
    Boyle, T.
    Lyu, B.
    Ballew, S.
    Selvin, E.
    Chang, A.
    Inker, L.
    Grams, M.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2023, 197
  • [22] Cardiorenal Protection: Potential of SGLT2 Inhibitors and GLP-1 Receptor Agonists in the Treatment of Type 2 Diabetes
    Taichi Nagahisa
    Yoshifumi Saisho
    Diabetes Therapy, 2019, 10 : 1733 - 1752
  • [23] Cardiorenal Protection: Potential of SGLT2 Inhibitors and GLP-1 Receptor Agonists in the Treatment of Type 2 Diabetes
    Nagahisa, Taichi
    Saisho, Yoshifumi
    DIABETES THERAPY, 2019, 10 (05) : 1733 - 1752
  • [24] Similar incidence of stroke with SGLT2 inhibitors and GLP-1 receptor agonists in real-world cohort studies among patients with type 2 diabetes
    Scheen, Andre J.
    DIABETES EPIDEMIOLOGY AND MANAGEMENT, 2024, 13
  • [25] Modulation of Cardiorenal Benefits for GLP-1RAs Treatment by GLP1R Genetic Variants
    Xue, Qiaochu
    Li, Piaopiao
    Pasquel, Francisco J.
    Phillips, Lawrence S.
    Liang, Donghai
    Narayan, K. M. Venkat
    Umpierrez, Guillermo
    Ali, Mohammed K.
    Shao, Hui
    DIABETES, 2024, 73
  • [26] Cardiovascular and kidney benefits of SGLT-2is and GLP-1RAs according to baseline blood pressure in type 2 diabetes: a systematic meta-analysis of cardiovascular outcome trials
    Kunutsor, Setor K.
    Seidu, Samuel
    Dey, Richard S.
    Baidoo, Isaac K.
    Oulhaj, Abderrahim
    SCANDINAVIAN CARDIOVASCULAR JOURNAL, 2024, 58 (01)
  • [27] Cardiovascular Benefits of SGLT2 Inhibitors and GLP-1 Receptor Agonists in Type 2 Diabetes
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2019, 61 (1566): : 26 - 28
  • [28] Real-world sex differences in type 2 diabetes patients treated with GLP-1 receptor agonists
    Piccini, Sara
    Favacchio, Giuseppe
    Morenghi, Emanuela
    Mazziotti, Gherardo
    Lania, Andrea G. A.
    Mirani, Marco
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2024, 212
  • [29] Use of SGLT2 Inhibitors vs GLP-1 RAs and Anemia in Patients With Diabetes and CKD
    Hu, Jia-Chian
    Shao, Shih-Chieh
    Tsai, Daniel Hsiang-Te
    Chuang, Albert Tzu-Ming
    Liu, Kuan-Hung
    Lai, Edward Chia-Cheng
    JAMA NETWORK OPEN, 2024, 7 (03) : E240946
  • [30] Real-World Weight Change, Adherence, and Discontinuation among Type 2 Diabetes (T2D) Patients Initiating GLP-1 Receptor Agonists (GLP-1RAs) in the UK
    Weiss, Tracey
    Iglay, Kristy
    Carr, Richard D.
    Mishra, Ajay Pratap
    Yang, Lingfeng
    Rajpathak, Swapnil
    DIABETES, 2019, 68
12345